Literature DB >> 6407404

Effects of artificial surfactant on lung function and blood gases in idiopathic respiratory distress syndrome.

A D Milner, H Vyas, I E Hopkin.   

Abstract

We have investigated the effect of giving two 25 mg doses of dry surfactant powder to the airways of 10 preterm babies with severe idiopathic respiratory distress syndrome requiring intermittent positive pressure ventilation. No useful change in static total compliance or blood gases was seen. We conclude that dry surfactant powder does not have a role in the management of severe idiopathic respiratory distress syndrome.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6407404      PMCID： PMC1627978          DOI： 10.1136/adc.58.6.458

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  5 in total

1.  Physical and physiological properties of dry lung surfactant.

Authors:  C J Morley; A D Banhham; P Johnson; G D Thorburn; G Jenkin
Journal:  Nature       Date:  1978-01-12       Impact factor: 49.962

2.  Artificial surfactant therapy in hyaline-membrane disease.

Authors:  T Fujiwara; H Maeta; S Chida; T Morita; Y Watabe; T Abe
Journal:  Lancet       Date:  1980-01-12       Impact factor: 79.321

3.  Critical assessment of jacket plethysmographs for use in young children.

Authors:  P Helms; B W Taylor; A D Milner; D J Hatch
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1982-01

4.  Sequential treatments of premature lambs with an artificial surfactant and natural surfactant.

Authors:  M Ikegami; A Jobe; H Jacobs; S J Jones
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

5.  A new method for measuring static compliance in infants and young children.

Authors:  A D Milner; D Hull; D J Hatch; J J Cogswell
Journal:  Clin Sci       Date:  1972-11       Impact factor: 6.124
  5 in total
  7 in total

Review 1.  Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome.

Authors:  T A Merritt; M Hallman; R Spragg; G P Heldt; N Gilliard
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 2.  Surfactant replacement therapy.

Authors:  M J Kresch; W H Lin; R S Thrall
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

3.  Early changes in lung function and response to surfactant replacement therapy.

Authors:  A T Gibson; R A Primhak
Journal:  Eur J Pediatr       Date:  1994-07       Impact factor: 3.183

4.  Effect of exogenous surfactant on total respiratory system compliance.

Authors:  A D Milner; H Vyas; I E Hopkin
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

5.  Replacement of surfactant in hyaline membrane disease.

Authors:  D V Walters
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-06

6.  Artificial surfactant in preterm rabbits with and without respiratory distress syndrome: difference of in vitro and in vivo activities.

Authors:  M Obladen; W Kampmann; I Zimmermann; B Lachmann
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

7.  Development and Characterization of Excipient Enhanced Growth (EEG) Surfactant Powder Formulations for Treating Neonatal Respiratory Distress Syndrome.

Authors:  Susan Boc; Mohammad A M Momin; Dale R Farkas; Worth Longest; Michael Hindle
Journal:  AAPS PharmSciTech       Date:  2021-04-15       Impact factor: 3.246
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.